Annual Stanford Metabolic Health Center Symposium

The Stanford Metabolic Health Center is hosting our next symposium virtually on Friday, February 26, 2021 from 9am to 12pm (Pacific Standard Time)

Join us to hear experts speak about the latest advancements in metabolomics!


9:00am – 9:20am: Michael Snyder, Ph.D, Stanford University. "Introduction to the Symposium and latest on the Stanford Metabolic Health Center" 

9:20am – 9:45am: Lars Ove Dragstad, Ph.D, University of Copenhagen. "Intake and effect assessment from metabolic profiles in human trials"

9:45am – 10:10am: Andrew Patterson, Ph.D, Penn State University. "Changing our perspective of bile acid biology through metabolomics"

10:10am – 10:30am: BREAK  (20 mins)

10:30am – 10:55am: Lorraine Brennan, Ph.D, University College Dublin. "Metabolomics in nutrition research: Current opportunities and developments"

10:55am – 11:20am: Robert Gerszten, MD, Harvard, Beth Israel, Broad Institute of MIT and Harvard. "Sifting through 120 terabytes of genomics data to gain insights into cardiometabolic diseases"

11:20am – 11:45am: Svati Shah, MD, MHS, Duke University. "Metabolic biomarkers in cardiometabolic disease"

11:45am – 12:00pm: Closing remarks


REGISTRATION is complimentary and REQUIRED for the event.  A Zoom link will be sent to the registrants the week of February 21, 2021.


Confirmed guest speakers for the 2021 Symposium:

Lorraine Brennan, Ph.D
Professor at University College Dublin and UCD Institute of Food and Health

Professor Lorraine Brennan is a Full Professor of Human Nutrition in University College Dublin, Ireland. Professor Brennan is at the forefront of nutrition and metabolomics research, running the Nutrition, Biomarkers, and Health research group, obtaining considerable National and European research funding and publishing high impact peer-reviewed articles. Her research focuses on developing novel biomarker methods to assess dietary intake and to combine biomarker approaches with self-reported data. She also has a focus on development of Precision Nutrition. Recent funding successes have included a European Research Council (ERC) Consolidator Award and US-Ireland tripartite grant. She is involved in a number of European consortia such as FoodBall and SusFood. Professor Brennan was a member of the EU Food2030 Expert group which assisted the European Commission with the development of FOOD2030 and explored possible future R&I policy recommendations and actions cumulating with a published report. 

Professor Brennan is Editor in Chief of Nutrition and Metabolism and Associate Editor for the American Journal of Clinical Nutrition. She has an active Public Engagement programme engaging with the local community in terms of Food and Nutrition.

Lars Ove Dragsted, Ph.D
Professor in Biomedicine and Nutrigenomics, Head of Preventative and Clinical Nutrition in the Department of Nutrition, Exercise and Sports, University of Copenhagen

Lars Ove Dragsted is Professor in Biomedicine and Nutrigenomics. He earned his PhD in Biochemical Toxicology from the University of Copenhagen and has worked in both public and private research organisations with a focus on bioactive food components, chronic disease prevention and biomarker development. In the area of metabolomics his group has contributed with a range of human intervention studies to identify novel biomarkers of food and dietary intake and to predict metabolic changes and disease development. Recent research has focussed on the concept of biomarkers, biomarker combination, food intake biomarkers, and on the imprint of the microbiota on the metabolome.  Lars Ove Dragsted is currently heading the Preventive and Clinical Nutrition group at the Department of Nutrition, Exercise and Sports at the University of Copenhagen.

Robert E. Gerszten, MD
Chief of Cardiovascular Medicine at Beth Israel Deaconess Medical Center
Herman Dana Professor of Medicine at Harvard Medical School 
Senior Associate Member of the Broad Institute

Dr. Gerszten graduated from the Johns Hopkins University School of Medicine, did his residency at the University of Pennsylvania, and his clinical fellowship in Cardiology at Massachusetts General Hospital.  Over the past decade, the Gerszten laboratory has built a nationally recognized program in translational research, integrating emerging metabolomic and proteomic approaches towards the identification of novel disease pathways and biomarkers.  An area of particular focus is the application of these tools to identify those most likely to benefit from clinical interventions in cardiometabolic diseases.  His highly interactive program collaborates across a spectrum of institutions, from the Broad Institute to the Framingham Heart Study and the TIMI Study Group. 

Andrew Patterson, Ph.D
Tombros Early Career Professor and Professor of Molecular Toxicology, Scientific Director of Metabolomics, Pennsylvania State University

Dr. Patterson is the Tombros Early Career Professor and Professor of Molecular Toxicology at the Pennsylvania State University, University Park, PA and is the Scientific Director of Metabolomics. He holds joint appointments in the Department of Veterinary and Biomedical Sciences and the Department of Biochemistry and Molecular Biology. He and his students, postdocs, and collaborators focus on understanding the host-metabolite-microbiota communication network—specifically how the manipulation of gut microbiota by diet and/or xenobiotics impacts host metabolites (e.g., bile acids, short chain fatty acids), their metabolism, and how these co-metabolites interact with host ligand-activated transcription factors. The lab employs a variety of tools, including NMR- and mass spectrometry-based metabolomics, genomics, and conventional and gnotobiotic transgenic mice, to facilitate its study of these pathways and understand their impact on human health and disease. 

Svati Shah, MD, MHS
Associate Dean of Genomics, Director of Precision Genomics Collaboratory at Duke School of Medicine
Vice-Chief of Translational Research and Director of the Adult Cardiovascular Genetics Clinic in the Division of Cardiology, Department of Medicine
Co-Director of Translational Research in the Duke Molecular Physiology Institute (DMPI)
Faculty member in the Duke Clinical Research Institute (DCRI)

Dr. Shah's research focus is on metabolic and genetic pathways of cardiometabolic diseases, integrating diverse genomic, metabolomic and proteomic techniques for identification of novel mechanisms of disease and biomarkers. Her multi-disciplinary molecular epidemiology lab within the DMPI has quantitative and molecular components and leverages large biorepositories on to perform discovery studies using omics technologies, with subsequent functional validation for mechanistic insight.

Michael P. Snyder, Ph.D
Stanford University Ascherman Professor and Chair of Genetics, Director of the Center of Genomics and Personalized Medicine, Co-Director of the Stanford Metabolic Health Center, Stanford University

Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and multiomics, and one of the major participants of the ENCODE project. His laboratory study was the first to perform a large-scale functional genomics project in any organism, and has developed many technologies in genomics and proteomics. These including the development of proteome chips, high resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor (TF) binding sites (ChIP-chip now replaced by ChIP-seq), paired end sequencing for mapping of structural variation in eukaryotes, de novo genome sequencing of genomes using high throughput technologies and RNA-Seq. These technologies have been used for characterizing genomes, proteomes and regulatory networks. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated (e.g. lncRNAs and TF binding sites), and a high diversity of transcription factor binding occurs both between and within species. He launched the field of personalized medicine by combining different state-of–the-art “omics” technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of a person, and his laboratory pioneered the use of wearables technologies (smart watches and continuous glucose monitoring) for precision health. He is a co-founder of many biotechnology companies, including Personalis, SensOmics, Qbio, January, Protos, Oralome, Mirvie and Filtricine.

For any questions regarding the symposium, please reach out to Casandra Trowbridge at

Symposium Sponsor


Photos from the Stanford Metabolic Health Center Symposium 2019 above.